SARS-CoV-2 Spike Antibodies for Broad Variant Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing vaccines and antibody treatments for COVID-19 have reduced efficacy against emerging variants of SARS-CoV-2, necessitating the development of medicaments that can effectively prevent and treat infections caused by these variants.
Innovation Solution
Development of antibodies and antigen-binding fragments that specifically bind to the spike protein of SARS-CoV-2, including compositions and combinations of antibodies with defined CDR sequences, which neutralize various SARS-CoV-2 variants with high potency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing vaccines and antibody treatments are used, then initial protection against SARS-CoV-2 is achieved, but efficacy against emerging variants deteriorates
Solution Approach 1:
The patent develops new antibody compositions with modified parameters including novel CDR sequences and bivalent structures that maintain high binding affinity across multiple SARS-CoV-2 variants, effectively adapting the therapeutic approach to counter variant evolution while preserving neutralization efficacy
Solution Approach 2:
The invention creates composite antibody molecules consisting of heavy and light chain variable regions with specifically engineered CDRs that form a bivalent structure capable of simultaneously recognizing conserved epitopes across different SARS-CoV-2 variants, thereby achieving broad-spectrum neutralization
2Reliability
If monoclonal antibodies are developed for specific variants, then high neutralization potency is achieved, but broad spectrum coverage deteriorates
Solution Approach 1:
The patent engineers antibody variable regions with CDRs that simultaneously target conserved epitopes across multiple SARS-CoV-2 variants including D614G, alpha, beta, gamma, delta, and mu, enabling a single antibody composition to perform multiple neutralization functions across diverse viral strains while maintaining high potency
Data Source
AI summary
The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 and methods of making and using the same. The antibodies can be used, for example, in prophylaxis, post-exposure prophylaxis, or treatment of SARS-CoV-2 infection. The antibodies can also be used to detect SARS-CoV-2, e.g., an infection in subject.